Compare VIRT & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIRT | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | 1027 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.5B |
| IPO Year | 2014 | 2018 |
| Metric | VIRT | DNTH |
|---|---|---|
| Price | $68.72 | $111.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $45.60 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.3M | 718.6K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 72.73 | N/A |
| EPS | ★ 3.62 | N/A |
| Revenue | ★ $3,632,118,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.34 | $29.48 |
| P/E Ratio | $16.90 | ★ N/A |
| Revenue Growth | ★ 26.25 | N/A |
| 52 Week Low | $31.55 | $22.81 |
| 52 Week High | $68.02 | $117.88 |
| Indicator | VIRT | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 69.40 | 54.51 |
| Support Level | $55.11 | $79.27 |
| Resistance Level | N/A | $114.55 |
| Average True Range (ATR) | 3.13 | 5.11 |
| MACD | 0.94 | -0.55 |
| Stochastic Oscillator | 93.92 | 42.67 |
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.